Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085580 (
essential hypertension
)
14,686
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aim of the study was to evaluate the effects of a 6 month treatment with doxazosin on blood pressure profile, left ventricular morphology and function and microalbuminuria in non diabetics patients with mild to moderate
essential hypertension
. We selected 12 patient (7 men and 5 women, mean age 47 + 8) with left ventricular (LV) hypertrophy (men LV mass index > 130g/m2, women LV mass index > 110 g/m2) and normal (< 56 mm) LV diastolic diameter at the basal evaluation. Echocardiogram, 24-hour blood pressure monitoring and microalbuminuria have been evaluated after 3 weeks of placebo and 6 months of oral treatment with doxazosin (2 mg once daily). We evaluated: heart rate, 24-hour, day-time and night-time systolic and diastolic blood pressure, LV mass index (LVMi), peak shortening rate (-dD/dt) and peak lengthening rate (+dD/dt) of LV diameter, and systolic wall stress (
ESS
). At the basal evaluation +dD/dt was reduced (< 3.6 sec-1) in 9 patients; -dD:dt was normal (> 1.9 sec-1) in all. Bun and creatinine was normal before and after treatment. After treatment +dD/dt increased in all patients, with normalization in 7 patient with basal diastolic impairment.
ESS
and -dD/dt were normal at the basal evaluation and did not change after therapy. The % reduction of LV mass significantly correlated with % decrease of 24-hour (r = 0.71) and day-time systolic BP (r = 0.86) and 24-hour (r = 0.69) and day-time diastolic BP (r = 0.81). In conclusion, treatment with doxazosin is able to induce regression of LV hypertrophy and significantly reduce microalbuminuria.
...
PMID:[Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension]. 892 64
Cardiac function was evaluated in rest and after exercise on a cycloergometer in 20 patients with
essential hypertension
(EH) aged 14 to 19 years and 12 age-matched healthy volunteers. Selected parameters of ECHO examination and mitral flow were assessed, including SV, CO, CI, %SF, EF, LIVDd, IVSd, LVPWd, LVMI, total peripheral vascular resistance,
ESS
, velocity of wave E. A and E/A index. In all cases, serum ET1 and NPY levels were measured in rest and after exercise, before and after 6-month enalapril therapy. The ETI serum level in hypertensive patients did not differ from controls, while the NPY level was significantly higher in hypertensives. Exercise did not affect the ETI serum concentration, however, it did increase the NPY level. Enalapril therapy had no effect on serum peptide concentrations. Correlation of the ETI serum level with ECHO parameters, including CO, Cl, SV, LIVDd, LVPWd, %SF, TPRI and wave E velocity, as well as correlation of NPY concentration with LIVDd, LVPWd, LVMI,
ESS
and wave E and A velocity may suggest that these peptides influence left ventricle function and structure disturbances in children with EH.
...
PMID:[Vasoactive peptides, endothelin 1 and neuropeptide Y, and total peripheral vascular resistance in children with essential hypertension]. 892 85